drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T)
drug_description
Autologous T cells engineered ex vivo with a chimeric antigen receptor to recognize a B-cell antigen and eliminate pathogenic B cells to suppress humoral autoimmunity in IgA nephropathy and primary membranous nephropathy; administered at 0.5×10^8 or 1×10^8 cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo with a chimeric antigen receptor that recognizes a B‑cell antigen. Upon infusion, the CAR-T cells bind and kill B cells, depleting autoreactive/antibody‑producing clones to suppress humoral autoimmunity and reduce pathogenic immune complexes in IgA nephropathy and primary membranous nephropathy.
drug_name
IM19 chimeric antigen receptor T cells (CAR-T)
nct_id_drug_ref
NCT06690359